Xolair® (omalizumab) PBS pricing information - 1 August 2024

Advance notice of 1 February 2025 change in Authority level for saxagliptin with dapagliflozin (Qtern® 5/10) - 1 August 2024

PBS Website Update - 1 August 2024

July 2024

Agenda for the November 2024 PBAC meeting – 31 July 2024

PBAC Public Summary Documents – March 2024 meeting (first time decisions not to recommend and deferrals) - 19 July 2024

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 19 July 2024

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 19 July 2024

Updates to the HTA Policy and Methods Review - 10 July 2024

Post-market Review workplan (May 2024) published - 8 July 2024

PBAC Public Summary Documents – March 2024 meeting - 5 July 2024

Expansion of the CTG PBS Co-Payment Program - 1 July 2024

Update - 13485R - CALCIUM, calcium carbonate 1.25 g (calcium 500 mg) chewable tablet, 120 (Cal-500) – Prescriber code permissions - 1 July 2024

PBS Website Update - 1 July 2024

June 2024

2024-25 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP - 28 June 2020

PBAC Update June 2024 - 25 June 2024

Outcomes of the May 2024 PBAC Intracycle meeting - 21 June 2024

Update - Substitution for new brand of Budesonide + Formoterol listings - 13 June 2024

1 June 2024 updates as part of the Digital Transformation of Authority Required (Written) PBS listings - 1 June 2024

PBS restriction changes to type 2 diabetes mellitus (T2DM) medicines - 1 June 2024

PBS Website Update - 1 June 2024

May 2024

Historical Archive of PBS Schedules from 1951 to 2002 - 23 May 2024

Drug Utilisation Sub-Committee (DUSC) utilisation analysis of medicines for type 2 diabetes - 21 May 2024

PBS subsidy arrangements for abatacept 125 mg SSSI - 15 May 2024

Updated Agenda for the July 2024 PBAC meeting – 10 May 2024

Agenda for the May 2024 PBAC Intracycle meeting - 3 May 2024

PBS Website Update - 1 May 2024

April 2024

Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – March 2024 - 26 April 2024

Publication of Stage 1 and Stage 2 PBS Process Improvements metrics report for 2022-23 - 19 April 2024

Updates to the HTA Policy and Methods Review Reference Committee – 15 April 2024

PBAC Public Summary Documents – December 2023 meeting - 5 April 2024

Agenda for the July 2024 PBAC meeting – 3 April 2024

National Health (Pharmaceutical Benefits) Regulations 2017 amendments - 3 April 2024

Public Consultation: Draft 2024-25 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP - 2 April 2024

1 April 2024 designated brand list – minimum stockholding requirements - 1 April 2024

PBS Website Update - 1 April 2024

March 2024

Stocktake of PBS medicines available for endometriosis and related conditions Report - 28 March 2024

Updates to the HTA Policy and Methods Review Reference Committee – 26 March 2024

Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents - 22 March 2023

Drug Utilisation Sub-Committee (DUSC) Outcome Statement - 22 March 2024

PBAC Chair and MSAC Chair and Deputy Chairs EOI outcome - 22 March 2024

Consultation Open: Co-design of an Enhanced Consumer Engagement Process - 18 March 2024

PBAC Public Summary Documents (first time decisions not to recommend and deferrals) – November 2023 meeting - 15 March 2024

Updates to the HTA Policy and Methods Review Reference Committee – 8 March 2024

Updated Agenda for March 2024 PBAC Meeting – 6 March 2024

Pharmaceutical Reform Agreement (PRA) Review Report - 6 March 2024

PBAC Public Summary Documents – November 2023 meeting - 1 March 2024

PBS arrangements due to discontinuation of Ordine 10 (morphine hydrochloride trihydrate) oral liquids effective 1 March 2024 - 1 March 2024

Nurse practitioner and endorsed midwife prescribing: consultation survey live - 1 March 2024

PBS Website Update - 1 March 2024